Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!! -- Ignore unavailable to you. Want to Upgrade?

To: Jeff Chan who wrote (70)	4/9/1999 2:07:00 PM
From: Pawl	Read Replies (1) \| Respond to of 86

News!! About other potential products. ---------------------------------------------------------------------- IGT Pharma Inc IGT Shares issued 8,819,820 Apr 8 close $0.66 Fri 9 Apr 99 News Release Mr. Bruce Schmidt reports The Science Council of British Columbia has awarded a Technology B.C. industry grant to develop a novel class of podophyllotoxin analogues (IPAs) as new anticancer agents for the treatment of various cancers including those that are multidrug resistant (MDR). IGT scientists have discovered and demonstrated that a specific class of IPAs exhibit potent antitumour activity against various cancer tumour types that are resistant to other anticancer drugs. The award will support key developmental and commercialization processes in the company's cancer program to bring new therapies through the product pipeline from the lab into the clinic. The award will assist IGT in accelerating the development of IPAs in the areas of drug chemistry, formulation and pharmacology. This information will help IGT scientists to custom design IPAs chemical structure for optimal therapeutic effect. Efficacy studies with various tumour models will determine a toxicity profile and identify dosing regimens for therapeutic activity. Preclinical studies will result in the identification of a final chemical and dosage form of the drug. The drug will be developed further in formal studies sufficient to support an investigational new drug (IND) submission in North America to allow for human trials. There are approximately 1.5 million new patients diagnosed with cancer annually in North America, of which 40 per cent fail to respond to any kind of therapy. The failure of anticancer drug therapy due to multidrug resistance is a major treatment problem. Cancer cells often appear to respond to chemotherapy, only to reappear completely tolerant to the drug or drug combinations that were initially effective. Current approaches to treating MDR cancers involve chemotherapies and chemosynsitizers, none of which are particularly effective. Development of a new IGT drug may offer a therapeutic solution to the lack of effective therapies for MDR in the cancer market. IGT Pharma has completed its private placement of 315,000 units at 75 cents, each unit consisting of one share and one-half of a warrant. A whole warrant is required to purchase an additional share at 90 cents until Feb. 23, 2000, and at $1.05 per share until Feb. 23, 2001. IGT has filed a short hold annual information form and accordingly these securities will become free trading on June 23, 1999. ----------------------------------------------------------------------